Certain Restricted stock units of BioSig Technologies, Inc. are subject to a Lock-Up Agreement Ending on 1-OCT-2021.
October 30, 2021
Share
Certain Restricted stock units of BioSig Technologies, Inc. are subject to a Lock-Up Agreement Ending on 1-OCT-2021. These Restricted stock units will be under lockup for 91 days starting from 2-JUL-2021 to 1-OCT-2021.
Details:
The executive officers, directors and certain of the stockholders have entered into lock-up agreements with the underwriters pursuant to which each of these persons or entities, with limited exceptions, may not, directly or indirectly, without the prior written consent of Laidlaw & Company (UK) Ltd.: (1) offer for sale, sell, contract to sell, pledge, or otherwise dispose of (or enter into any transaction or device that is designed to, or could be expected to, result in the disposition by any person at any time in the future of), directly or indirectly, any shares of common stock (including, without limitation, shares of common stock that may be deemed to be beneficially owned by the undersigned in accordance with the rules and regulations of the SEC and shares of common stock that may be issued upon exercise of any options or warrants) or securities convertible into or exercisable or exchangeable for common stock, for a period of 90 days after the date of the final prospectus supplement for this offering.
BioSig Technologies, Inc. is a medical technology company focused on deciphering the bodyâs electrical signals, starting with heart rhythms. The Companyâs product, the PURE EP Platform, a non-invasive class II device, provides real-time signal visualization allowing physicians to perform highly targeted cardiac ablation procedures. Integrating with existing systems in the EP lab, PURE EP is designed to pinpoint even the complex signals to maximize procedural success and efficiency. The PURE EP System is designed to address long-standing limitations that slow and disrupt cardiac catheter ablation procedures, such as environmental lab noise from other equipment, signal saturation, slow signal recovery, and inaccurate display of fractionated potentials. PURE EP is a signal processing platform that combines advanced hardware and software to address known challenges associated to signal acquisition, to enable electrophysiologists to see more signals and analyze them in real-time.